Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Chemical Abortion topic
No spam. Unsubscribe anytime.
Committee hears first hearing on bill to require standardized consent and civil remedies for chemical‑abortion complications
Summary
At the Senate Health Committee’s first hearing on Senate Bill 309, a proponent urged standardized consent about chemical‑abortion risks and new enforcement authority for the attorney general, citing FDA REMS changes and insurance‑claims data; committee members pressed for peer‑reviewed evidence and clarification on recordkeeping and causation in litigation.
A proponent of Senate Bill 309 told the Senate Health Committee that the bill would require standardized consent and give the attorney general enforcement authority against chemical‑abortion providers if complications occur.
The presenter said SB 309 — described in testimony as the Abortion Pill Provider Liability Education (APPLE) Act — would direct the Department of Health to develop a clear consent form so women and their families are aware of the risks of mifepristone and misoprostol and of their right to pursue civil remedies if complications arise. "This bill is an opportunity for abortion providers to ensure their patients are properly informed and reevaluate their desire to be held legally liable in offering this drug," the presenter said during opening remarks.
Why it matters: The presenter cited federal Food and Drug Administration (FDA) REMS (risk evaluation and mitigation strategies) changes since 2000 — including loosened in‑person requirements and the 2021 expansion allowing telehealth dispensing — and argued that broader access has increased the need for mandated counseling about complications and follow‑up care. The testimony included claims from insurance‑claims analyses and referenced FDA post‑market reports of deaths and hospitalizations after mifepristone.
Discussion and evidence: Committee members questioned the necessity of a new statutory requirement given existing informed‑consent practices. A senator asked whether litigation would require proof that the drug caused a particular death or complication; the presenter replied that causation would be litigated in court but maintained that mandated counseling would help ensure patients know to seek care if complications arise. Another senator asked who would keep signed consent forms; the presenter said the provider who obtains the signature would retain the form in their records.
Several committee members challenged the data cited in testimony. One asked whether the presenter relied on peer‑reviewed, evidence‑based studies, calling a cited policy‑center report "self‑published." The presenter said additional expert witnesses and insurance‑claims analyses would be provided in later hearings and reiterated that reporting of nonfatal complications had changed in recent years, limiting what federal reports currently capture.
What the hearing did not decide: The committee closed the first hearing without taking a vote on SB 309. No statutory text was amended on the record and the committee solicited additional expert evidence and testimony.
Next steps: The bill will return to further hearings; the committee did not announce a timetable for additional testimony or a vote.
